(Q45779905)

16 December 2017

title

Development and significance of zidovudine resistance in children infected with human immunodeficiency virus (English)

1 reference

16 December 2017

1 reference

Ogino MT

1

1 reference

16 December 2017

Dankner WM

series ordinal

2

1 reference

16 December 2017

Spector SA

series ordinal

3

1 reference

16 December 2017

language of work or name

English

0 references

publication date

1 July 1993

1 reference

16 December 2017

The Journal of Pediatrics

published in

1 reference

16 December 2017

volume

123

1 reference

16 December 2017

issue

1

1 reference

16 December 2017

page(s)

1-8

1 reference

16 December 2017

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

HIV-1 sensitivity to zidovudine and clinical outcome in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

CD4 status and P24 antigenemia. Are they useful predictors of survival in HIV-infected children receiving antiretroviral therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Growth failure as a prognostic indicator for progression to acquired immunodeficiency syndrome in children with hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

inferred from DOI database lookup

7 January 2021

based on heuristic

p24 antigenaemia, CD4 lymphocyte counts and the development of AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981529-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(05)81529-X

1 reference

16 December 2017

release_7jwyyikherbdjmgx5esiwwdy24

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7jwyyikherbdjmgx5esiwwdy24

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

8100579

1 reference

16 December 2017